It's in EU, but not all EU countries allows medicinal cannabis
ok.. just say MGC has the licence, from the economy of scale point of view, I can hardly see MGC can compete with other bigger players in the market.
MGC has too many projects, Cannapil, different creams etc... where MGC gonna get the money to fuel these projects? from their last financial reports, they hardly have any substance revenue.
From the experience of QBL, it's definitely a sell signal to me
MXC Price at posting:
7.5¢ Sentiment: None Disclosure: Not Held
